

**MEETING MINUTES  
OF THE  
CENTERS FOR MEDICARE AND  
MEDICAID SERVICES**

**MEDICARE EVIDENCE DEVELOPMENT  
AND  
COVERAGE ADVISORY COMMITTEE**

August 20, 2008

Centers for Medicare and Medicaid Services  
7500 Security Boulevard  
Woodlawn, Maryland

**Medicare Evidence Development and Coverage  
Advisory Committee**

**August 20, 2008**

**Attendees**

**Acting Chair**

Saty Satya-Murti, M.D., F.A.A.N.

**Panel Members**

I. Craig Henderson, M.D.

Nora A. Janjan, M.D.

J. Leonard Lichtenfeld, M.D.

Andrew Sloan, M.D.

**CMS Liaison**

Steve E. Phurrough, M.D., M.P.A.

**Consumer Representative**

Linda A. Bergthold, Ph.D.

**Industry Representative**

Peter Juhn, M.D., M.P.H.

**Guest Panel Member**

Richard I. Wahl, M.D.

**Executive Secretary**

Maria A. Ellis

**Wednesday, August 20, 2008, 8:07 a.m.**

The Medicare Evidence Development and Coverage Advisory Committee met on August 20, 2008, to discuss the evidence, hear presentations and public comments, and make recommendations concerning the oncologic indications of FDG Positron Emission Tomography, or PET, for nine cancers: brain, cervical, small cell lung, ovarian, pancreatic, testicular, prostate, bladder, and kidney.

The meeting began with a discussion of conflict of issue matters, opening remarks by the CMS liaison and acting chair, followed by an introduction of the panel members.

**CMS Presentation and Voting Questions**

The lead analyst for this meeting presented the panel with the goals and agenda for the meeting and read the questions that would be discussed and voted upon by the panel. He also listed the materials with which the panel had been provided. The lead analyst also discussed the current policy for Medicare coverage of FDG-PET and FDGPET/CT, in particular for oncologic indications.

**Technology Assessment Presentation**

Results of the technology assessment were presented by representatives of the Evidence-Based Practice Group from the University of Alberta.

**Guest Speakers**

The panel heard from two invited guest speakers. The first discussed the development of the National Oncology PET Registry, or NOPR, to assess the effect of FDG-PET on referring physicians' plan of intended patient management across the spectrum of expanded cancer indications for PET as well as the one- and two-year findings of the Registry.

The second speaker presented additional information and data from a combination of societies that are experts in cancer imaging, as well as cancer care and treatment.

Following this, both speakers responded to questions from the panel.

### **Scheduled Public Speakers**

The panel heard from a representative of the Ovarian Cancer National Alliance and also a representative from the International Myeloma Foundation.

### **Open Comments**

The panel was addressed by a professor of radiology from Washington University and NOPR working group co-chair; a professor of radiology and director of nuclear medicine at Duke University; a medical oncologist from Wayne State University and Karmanos Cancer Institute; and a representative from the Center for Medical Technology Policy.

### **Questions**

An extensive question and answer session was held between the panel, the presenters, and those who made comments.

### **Initial Panel Discussion**

The panel conducted an extensive discussion prior to casting their votes.

### **Formal Remarks and Voting**

The panel voted on the voting questions. Panelists displayed their numerical votes to be recorded by staff. Each panelist then explained the reasoning behind their vote.

### **Final Panel Discussion**

After the voting, the panelists were asked to comment on the direction they would

recommend CMS to pursue in terms of further study on the use of FDG-PET and FDG-PET/CT for oncologic indications.

**Final Remarks**

Before adjourning, Dr. Phurrough thanked the panelists and the other participants for their efforts.

**Adjournment**

The meeting was adjourned at 3:27 p.m.

I certify that I attended the meeting of the  
MedCAC Committee on August 20, 2008,  
and that these minutes accurately reflect  
what transpired.

/S/

Maria A. Ellis

Executive Secretary, MedCAC, CMS

I approve the minutes of this meeting  
as recorded in this summary.

/S/

Saty Satya-Murti, M.D., F.A.A.N.

Acting Chair